Dyslipidemias
Solbinsiran: Eli Lilly’s Promising ANGPTL3 Inhibitor for Lipid Management
ANGPTL3 inhibition, solbinsiran, dyslipidemia, lipid reduction, siRNA therapy
Rona’s Sanofi-Sourced siRNA Demonstrates Early Efficacy in Dyslipidaemia Treatment
siRNA, dyslipidaemia, Rona, Sanofi, RNA interference, lipid disorders, therapeutic development
Arrowhead’s Plozasiran Projected to Surpass $700M in Sales by 2032, Addressing Major Unmet Needs in Dyslipidemia Treatment
Arrowhead Pharmaceuticals, Plozasiran, Dyslipidemia, GlobalData, Sales Forecast, $700M, 2032, Unmet Needs, Triglyceride Reduction, APOC3 Targeting, SHTG (Severe Hypertriglyceridemia), FCS (Familial Chylomicronemia Syndrome), Mixed Dyslipidemia